---
title: "WBDE: The first subject has been enrolled in the Phase II/III clinical trial of Shishanjianjia controlled-release tablets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255175145.md"
description: "WBDE announced that the Phase II/III clinical trial of its wholly-owned subsidiary WBDE Pharmaceutical Group Co., Ltd.'s donepezil controlled-release tablets for the treatment of mild to moderate Alzheimer's disease has completed the enrollment of the first subject. The drug utilizes a biphasic controlled-release technology aimed at improving the onset speed and safety of the medication, and supports once-daily dosing to enhance patient convenience and compliance. This trial will validate its clinical value and provide new options for Alzheimer's disease treatment"
datetime: "2025-08-29T10:21:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255175145.md)
  - [en](https://longbridge.com/en/news/255175145.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255175145.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/255175145.md) | [繁體中文](https://longbridge.com/zh-HK/news/255175145.md)


# WBDE: The first subject has been enrolled in the Phase II/III clinical trial of Shishanjianjia controlled-release tablets

WBDE announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., has completed the enrollment of the first subject in the Phase II/III pivotal registration clinical trial of the Class 2 new drug Huperzine A controlled-release tablets for the treatment of mild to moderate Alzheimer's disease dementia. Huperzine A controlled-release tablets utilize a biphasic controlled-release technology to smooth the drug release peak and trough curve, extending the drug release time in the body, thereby achieving rapid onset, reducing adverse reactions, and enhancing the dosage with good safety. At the same time, the controlled-release technology supports once-daily dosing, improving patient convenience and long-term adherence. This clinical trial will comprehensively validate the overall clinical value and benefits of Huperzine A controlled-release tablets, providing new options for Alzheimer's disease treatment

### Related Stocks

- [WBDE (002082.CN)](https://longbridge.com/en/quote/002082.CN.md)

## Related News & Research

- [Yangtze Optical Fibre and Cable Joint Stock Limited Company Announces Board Changes](https://longbridge.com/en/news/279077198.md)
- [CATL makes progress on its solid-state battery](https://longbridge.com/en/news/279018020.md)
- [Bank of America Securities Keeps Their Buy Rating on Contemporary Amperex Technology Co., Limited Class H (3750)](https://longbridge.com/en/news/278636079.md)
- [CATL Sets 2025 AGM to Approve Dividends, Financing Mandates and ESOP Plan](https://longbridge.com/en/news/278463674.md)
- [CATL Announces Final 2025 Dividend and Details Cross-Border Tax Treatment](https://longbridge.com/en/news/278474723.md)